NCT07664397尚未招募1 期
A Pilot PET Imaging Study of [89Zr]DFO-YS5 for Detection of Cancer in Patients With Various Malignancies
Robert Flavell, MD, PhD1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2026年8月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 40
- 试验地点
- 1
研究概览
简要总结
This is a single-center, pilot, PET-imaging study of the novel radiotracer 89Zirconium-89 DFO conjugated to the YS5 monoclonal antibody ([89Zr]DFO-YS5) in participants with nerve sheath tumor, bladder cancer, or advanced solid tumor neoplasms.
详细描述
PRIMARY OBJECTIVE:
I. To descriptively report patterns of [89Zr]DFO-YS5 uptake on whole-body PET.
SECONDARY OBJECTIVE:
II. To determine the safety of [89Zr]DFO-YS5.
OUTLINE:
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histological or cytological confirmation of malignant peripheral nerve sheath tumor, bladder cancer, or solid tumor neoplasm.
- •At least one soft tissue lesion measurable at 1 cm or greater in short axis measurement on cross sectional imaging such as Computerized tomography (CT), magnetic resonance imaging (MRI), or Positron Emission Tomography (PET)/CT (scan imaging as documented in the medical record). Exception: For participants with localized bladder cancer (pre-cystectomy), lesions smaller than 1 centimeter (cm) are permitted, provided there is cystoscopic confirmation of a bladder mass.
- •Clinically able to undergo PET-CT imaging or PET-MRI.
- •Age ≥ 18 years.
- •Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 or Karnofsky ≥ 50% (see Appendix 1).
- •Adequate organ function as defined below:
- •Total bilirubin: ≤ 1.5 x institutional upper limit of normal (ULN) (unless elevated due to Gilbert's syndrome and direct bilirubin is within normal limits).
- •Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase (SGOT)): ≤ 3 x ULN.
- •Alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase (SGPT)): ≤ 3 x ULN.
- •Estimated creatinine clearance: ≥ 60 mL/min, calculated using the Cockcroft-Gault equation.
- •Females of reproductive potential (defined below) must be willing to undergo a urine or serum pregnancy test (i.e., human chorionic gonadotropin test) within 72 hours before administration of [89Zr]DFO-YS
- •A female is considered to NOT be of reproductive potential (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice), if they meet either of the following two criteria: (1) has reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause); or (2) has undergone surgical sterilization (i.e., hysterectomy and/or bilateral oophorectomy for removal of uterus and/or ovaries). The result of the urine or serum pregnancy test must be negative in order to initiate the [89Zr]DFO-YS5 administration. If a urine pregnancy test is positive or equivocal, a confirmatory a serum pregnancy test is required. The individual must be excluded from participation if the serum pregnancy result is positive. Pregnant individuals are excluded from this study because there is an unknown but potential risk for adverse effects in the unborn child secondary to treatment of the study participant with [89Zr]DFO-YS
- •Individuals with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or endpoints of this study are eligible.
- •Ability to understand and the willingness to sign a written informed consent document.
排除标准
- •Individuals with a contraindication to PET-CT imaging (e.g., severe claustrophobia) or PET-MRI (e.g., implanted devices, metallic objects, or other implants). Participants must be able to undergo either PET-CT or PET-MRI.
- •Individuals who are pregnant or breastfeeding/chest-feeding. Pregnant and breastfeeding/chest-feeding individuals are excluded because there is an unknown but potential risk for adverse effects in the unborn/nursing child secondary to treatment of the study participant with [89Zr]DFO-YS
- •Females of childbearing potential must have a negative pregnancy test before administration of [89Zr]DFO-YS5, as outlined in inclusion criterion #
- •Breastfeeding/chest-feeding should be discontinued before administration of [89Zr]DFO-YS
- •Individuals who do not agree to follow the below contraception requirements:
- •Females of reproductive potential (defined below) must agree to use two forms of contraception, consisting of a barrier method (such as condoms) in combination with a secondary complementary method (such as hormonal, Intrauterine device (IUD), etc.), or strict abstinence, for the duration of study participation and for 1 month after administration of [89Zr]DFO-YS
- •A female is considered to NOT be of reproductive potential (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice), if they meet either of the following two criteria: (1) has reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause); or (2) has undergone surgical sterilization (i.e., hysterectomy and/or bilateral oophorectomy for removal of uterus and/or ovaries).
- •Hypersensitivity to [89Zr]DFO-YS5 or any of its excipients.
- •Individuals with any condition or social circumstance that, in the opinion of the investigator, would impair the participant's ability to comply with study procedures.
研究者
Robert Flavell, MD, PhD
Principal Investigator
University of California, San Francisco
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple MyelomaPlasma Cell MyelomaMultiple MyelomaNCT05892393Robert Flavell, MD, PhD20
招募中
3 期
Evaluating T Cell Changes and Activation in Cancer Patient Using Two PET Tracers (iRelate)MelanomaEsophageal CancerBreast cancer2023-509486-20-00Amsterdam UMC34
招募中
1 期
PET [89Zr]DFO-starPEG in Solid TumorsNCT06894745Robert Flavell, MD, PhD13
招募中
1 期
FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing DiseasePituitary AdenomaNCT07460232Mayo Clinic50
招募中
不适用
Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid TumorsSolid TumorsNCT07529002Peking University Cancer Hospital & Institute20